Ticagrelor was not superior to clopidogrel to reduce heart attack risk during angioplasty
The ALPHEUS trial found no significant difference in periprocedural heart attack and complications between ticagrelor and clopidogrel in patients undergoing elective PCI. The study suggests that ticagrelor should be reserved for acute coronary syndrome cases, not those with stable heart conditions.